

Accordingly, upon determination of allowability of the presently elected claims of Group IV, Applicants intention is to additionally present claims directed generally to: a method of modulating the physiology or development of a cell or tissue culture cells comprising introducing an agonist or antagonist of a  
5 499E9 (Group V); and a method of modulating the physiology or development of a cell or tissue culture cells comprising contacting the cell with a nucleic acid encoding a 499E (Group VI), along with other methods of making and using  
nucleic acids.

Should the restriction be made final, Applicants will subsequently address  
10 the issue of inventorship for the selected claims and amend inventorship accordingly, if required.

Applicant believes no fees are presently due. If, however, any fees are necessitated by the present response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account  
15 No. 04-1239.

Respectfully submitted,

20 Dated: October 1, 1998

Edwin P. Ching  
Edwin P. Ching  
Reg. No. 34,090

25 DNAX Research Institute  
901 California Avenue  
Palo Alto, California 94304-1104  
Tel: 650-852-9196  
Fax: 650-496-1200